Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $70 | $46 | $78 | $230 |
| - Cash | $35 | $42 | $39 | $40 |
| + Debt | $3 | $3 | $4 | $4 |
| Enterprise Value | $37 | $7 | $42 | $194 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$18 | -$21 | -$19 | -$23 |
| % Margin | – | – | – | – |
| Net Income | -$18 | -$21 | -$20 | -$23 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.47 | -0.55 | -0.51 | -0.6 |
| % Growth | 14.5% | -7.8% | 15% | – |
| Operating Cash Flow | -$12 | -$17 | -$20 | -$17 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$13 | -$17 | -$20 | -$18 |